Ann Michelle Cunningham
CIK: 0001764572
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Cunningham Ann Michelle
Cunningham Ann Michelle (SEC CIK 0001764572) files insider reports with the SEC as Director of ALTERITY THERAPEUTICS LTD (ATHE) and Director of Vistagen Therapeutics, Inc. (VTGN).
Signal8 holds 3 ownership filings by Cunningham Ann Michelle (1 Form 3, 2 Form 4), filed between Sep 10, 2024 and Apr 29, 2026. Those filings report 2 transactions, from Sep 6, 2024 to Sep 9, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Cunningham Ann Michelle's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Cunningham Ann Michelle
Other insiders filing for ALTERITY THERAPEUTICS LTD (ATHE)
- Marks Peter Ashley, Director
- Stamler David Allen, Chief Executive Officer
- Babarczy Julian Michael, Director
- Gozlan Lawrence Bernard, Director
- Macnish Niven Abby Sarah, Chief Financial Officer